These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 26492214)

  • 1. A Time Trade-off-derived Value Set of the EQ-5D-5L for Canada.
    Xie F; Pullenayegum E; Gaebel K; Bansback N; Bryan S; Ohinmaa A; Poissant L; Johnson JA;
    Med Care; 2016 Jan; 54(1):98-105. PubMed ID: 26492214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How different are composite and traditional TTO valuations of severe EQ-5D-5L states?
    Xie F; Pullenayegum E; Gaebel K; Bansback N; Bryan S; Ohinmaa A; Poissant L; Johnson JA
    Qual Life Res; 2016 Aug; 25(8):2101-8. PubMed ID: 26875190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Value Set Based on DCE and/or TTO Data: Scoring for EQ-5D-5L Health States in Japan.
    Shiroiwa T; Ikeda S; Noto S; Igarashi A; Fukuda T; Saito S; Shimozuma K
    Value Health; 2016; 19(5):648-54. PubMed ID: 27565282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets.
    Law EH; Pickard AS; Xie F; Walton SM; Lee TA; Schwartz A
    Med Decis Making; 2018 Nov; 38(8):968-982. PubMed ID: 30403577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experience-Based Swedish TTO and VAS Value Sets for EQ-5D-5L Health States.
    Burström K; Teni FS; Gerdtham UG; Leidl R; Helgesson G; Rolfson O; Henriksson M
    Pharmacoeconomics; 2020 Aug; 38(8):839-856. PubMed ID: 32307663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of time trade-off valuations for EQ-5D-5L health states: data from the Canadian EQ-5D-5L valuation study.
    Sayah FA; Bansback N; Bryan S; Ohinmaa A; Poissant L; Pullenayegum E; Xie F; Johnson JA
    Qual Life Res; 2016 Jul; 25(7):1679-85. PubMed ID: 26659899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value set.
    Ferreira PL; Antunes P; Ferreira LN; Pereira LN; Ramos-Goñi JM
    Qual Life Res; 2019 Dec; 28(12):3163-3175. PubMed ID: 31201730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. United States Valuation of EQ-5D-5L Health States Using an International Protocol.
    Pickard AS; Law EH; Jiang R; Pullenayegum E; Shaw JW; Xie F; Oppe M; Boye KS; Chapman RH; Gong CL; Balch A; Busschbach JJV
    Value Health; 2019 Aug; 22(8):931-941. PubMed ID: 31426935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valuation of the EQ-5D-5L with composite time trade-off for the German population - an exploratory study.
    Ludwig K; von der Schulenburg JG; Greiner W
    Health Qual Life Outcomes; 2017 Feb; 15(1):39. PubMed ID: 28219389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dutch Tariff for the Five-Level Version of EQ-5D.
    M Versteegh M; M Vermeulen K; M A A Evers S; de Wit GA; Prenger R; A Stolk E
    Value Health; 2016 Jun; 19(4):343-52. PubMed ID: 27325326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The EQ-5D-5L Valuation study in Thailand.
    Pattanaphesaj J; Thavorncharoensap M; Ramos-Goñi JM; Tongsiri S; Ingsrisawang L; Teerawattananon Y
    Expert Rev Pharmacoecon Outcomes Res; 2018 Oct; 18(5):551-558. PubMed ID: 29958008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valuing Health State: An EQ-5D-5L Value Set for Ethiopians.
    Welie AG; Gebretekle GB; Stolk E; Mukuria C; Krahn MD; Enquoselassie F; Fenta TG
    Value Health Reg Issues; 2020 Sep; 22():7-14. PubMed ID: 31683254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The EQ-5D-5L Valuation Study in Egypt.
    Al Shabasy S; Abbassi M; Finch A; Roudijk B; Baines D; Farid S
    Pharmacoeconomics; 2022 Apr; 40(4):433-447. PubMed ID: 34786590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating a social value set for EQ-5D-5L in Sweden.
    Sun S; Chuang LH; Sahlén KG; Lindholm L; Norström F
    Health Qual Life Outcomes; 2022 Dec; 20(1):167. PubMed ID: 36564844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The EQ-5D-5L valuation study for Trinidad and Tobago.
    Bailey H; Jonker MF; Pullenayegum E; Rencz F; Roudijk B
    Health Qual Life Outcomes; 2024 Jul; 22(1):51. PubMed ID: 38956543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigating 5-Level EQ-5D (EQ-5D-5L) Values Based on Preferences of Patients With Heart Disease.
    Gandhi M; Tan RS; Lim SL; Rand K; Lam CSP; Luo N; Cheung YB
    Value Health; 2022 Mar; 25(3):451-460. PubMed ID: 35227458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Censoring Time Trade-off Values at 0 Versus at -1: How Does the Assumption for Worse-Than-Dead Time Trade-off Values Affect the Modeling of EQ-5D-5L Valuation Data?
    Yang Z; Rand K; Luo N
    Value Health; 2023 May; 26(5):685-693. PubMed ID: 36375679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peruvian Valuation of the EQ-5D-5L: A Direct Comparison of Time Trade-Off and Discrete Choice Experiments.
    Augustovski F; Belizán M; Gibbons L; Reyes N; Stolk E; Craig BM; Tejada RA
    Value Health; 2020 Jul; 23(7):880-888. PubMed ID: 32762989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3125 steps to perfect health: a nonparametric approach to developing the EQ-5D-5L value set.
    Thomas S; Johnson JA; Xie F
    Qual Life Res; 2020 Nov; 29(11):3109-3118. PubMed ID: 32705459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The EQ-5D-5L valuation study in Korea.
    Kim SH; Ahn J; Ock M; Shin S; Park J; Luo N; Jo MW
    Qual Life Res; 2016 Jul; 25(7):1845-52. PubMed ID: 26961008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.